Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury.
concussive head injury
glucagon-like peptide-1
glucose-dependent insulinotropic polypeptide
incretin
liraglutide
traumatic brain injury
twincretin
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
09
2019
accepted:
10
12
2019
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
31
1
2020
Statut:
epublish
Résumé
Traumatic brain injury (TBI) is a commonly occurring injury in sports, victims of motor vehicle accidents, and falls. TBI has become a pressing public health concern with no specific therapeutic treatment. Mild TBI (mTBI), which accounts for approximately 90% of all TBI cases, may frequently lead to long-lasting cognitive, behavioral, and emotional impairments. The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones that induce glucose-dependent insulin secretion, promote β-cell proliferation, and enhance resistance to apoptosis. GLP-1 mimetics are marketed as treatments for type 2 diabetes mellitus (T2DM) and are well tolerated. Both GLP-1 and GIP mimetics have shown neuroprotective properties in animal models of Parkinson's and Alzheimer's disease. The aim of this study is to evaluate the potential neuroprotective effects of liraglutide, a GLP-1 analog, and twincretin, a dual GLP-1R/GIPR agonist, in a murine mTBI model. First, we subjected mice to mTBI using a weight-drop device and, thereafter, administered liraglutide or twincretin as a 7-day regimen of subcutaneous (s.c.) injections. We then investigated the effects of these drugs on mTBI-induced cognitive impairments, neurodegeneration, and neuroinflammation. Finally, we assessed their effects on neuroprotective proteins expression that are downstream to GLP-1R/GIPR activation; specifically, PI3K and PKA phosphorylation. Both drugs ameliorated mTBI-induced cognitive impairments evaluated by the novel object recognition (NOR) and the Y-maze paradigms in which neither anxiety nor locomotor activity were confounds, as the latter were unaffected by either mTBI or drugs. Additionally, both drugs significantly mitigated mTBI-induced neurodegeneration and neuroinflammation, as quantified by immunohistochemical staining with Fluoro-Jade/anti-NeuN and anti-Iba-1 antibodies, respectively. mTBI challenge significantly decreased PKA phosphorylation levels in ipsilateral cortex, which was mitigated by both drugs. However, PI3K phosphorylation was not affected by mTBI. These findings offer a new potential therapeutic approach to treat mTBI, and support further investigation of the neuroprotective effects and mechanism of action of incretin-based therapies for neurological disorders.
Identifiants
pubmed: 31998717
doi: 10.3389/fcell.2019.00356
pmc: PMC6965031
doi:
Types de publication
Journal Article
Langues
eng
Pagination
356Informations de copyright
Copyright © 2020 Bader, Li, Tweedie, Shlobin, Bernstein, Rubovitch, Tovar-y-Romo, DiMarchi, Hoffer, Greig and Pick.
Références
Psychopharmacology (Berl). 2011 Apr;214(4):877-89
pubmed: 21120456
J Neurosci. 2011 Apr 27;31(17):6587-94
pubmed: 21525299
J Clin Invest. 2013 Jun;123(6):2730-6
pubmed: 23728174
Anat Sci Int. 2004 Dec;79(4):209-12
pubmed: 15633459
Neuroscience. 2003;118(4):949-55
pubmed: 12732240
Neurobiol Dis. 2010 May;38(2):299-303
pubmed: 20138993
Exp Neurol. 2017 Feb;288:176-186
pubmed: 27845037
J Neurotrauma. 2016 Nov 15;33(22):2044-2054
pubmed: 26972789
Alzheimers Res Ther. 2013 Apr 19;5(2):20
pubmed: 23601582
Brain Inj. 2018;32(13-14):1858-1865
pubmed: 30346862
J Endocrinol. 2014 Mar 07;221(1):T31-41
pubmed: 23999914
Lancet Neurol. 2015 May;14(5):506-17
pubmed: 25801547
Mol Endocrinol. 2003 Feb;17(2):161-71
pubmed: 12554744
Mt Sinai J Med. 2009 Apr;76(2):97-104
pubmed: 19306379
JAMA Neurol. 2019 Apr 1;76(4):420-429
pubmed: 30640362
Behav Brain Res. 2017 Jun 1;327:65-74
pubmed: 28342971
J Neuroinflammation. 2012 Dec 23;9:276
pubmed: 23259618
Eur J Cell Biol. 2017 May;96(3):240-253
pubmed: 28336086
Epilepsia. 2003;44(s10):2-10
pubmed: 14511388
Biochem Biophys Res Commun. 2017 Jan 22;482(4):948-953
pubmed: 27908726
PLoS One. 2012;7(2):e32008
pubmed: 22384126
Eur J Pharmacol. 2017 Jun 5;804:38-45
pubmed: 28366809
Acta Neurobiol Exp (Wars). 2011;71(1):36-45
pubmed: 21499325
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
J Endocrinol. 2009 Sep;202(3):431-9
pubmed: 19570816
Metab Brain Dis. 2017 Oct;32(5):1735-1745
pubmed: 28681199
Peptides. 2011 Apr;32(4):781-9
pubmed: 21185343
Front Aging Neurosci. 2016 May 24;8:108
pubmed: 27252647
World J Diabetes. 2015 Jun 25;6(6):807-27
pubmed: 26131323
Cent Nerv Syst Agents Med Chem. 2011 Sep 1;11(3):210-22
pubmed: 21919873
J Neurosci Res. 2008 Feb 1;86(2):326-38
pubmed: 17803225
J Surg Res. 2016 Nov;206(1):67-76
pubmed: 27916377
Sci Transl Med. 2013 Oct 30;5(209):209ra151
pubmed: 24174327
Age (Dordr). 2013 Oct;35(5):1621-36
pubmed: 22892942
Lancet Neurol. 2008 Aug;7(8):728-41
pubmed: 18635021
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1285-90
pubmed: 19164583
Mol Psychiatry. 2018 Feb;23(2):177-198
pubmed: 29230021
J Neuroimmunol. 2018 Mar 15;316:17-22
pubmed: 29249556
Mol Endocrinol. 2001 Sep;15(9):1559-70
pubmed: 11518806
J Pathol. 2018 May;245(1):85-100
pubmed: 29435980
Diabetes Obes Metab. 2017 Oct;19(10):1436-1445
pubmed: 28730694
J Alzheimers Dis. 2010;19(4):1205-19
pubmed: 20308787
Mol Cell Neurosci. 2015 May;66(Pt B):75-80
pubmed: 25748121
Psychoneuroendocrinology. 2016 Mar;65:54-66
pubmed: 26724568
PLoS One. 2017 Apr 11;12(4):e0174847
pubmed: 28399158
Br J Anaesth. 2007 Jul;99(1):18-31
pubmed: 17545555
J Neurotrauma. 2005 Sep;22(9):1003-10
pubmed: 16156715
Neurosci Lett. 2009 Aug 7;459(2):52-6
pubmed: 19416748
Trends Pharmacol Sci. 2003 Jul;24(7):377-83
pubmed: 12871671
Expert Opin Ther Targets. 2018 Jul;22(7):615-628
pubmed: 29911915
Neurosci Res. 2006 Aug;55(4):352-60
pubmed: 16720054
Neuropharmacology. 2016 Feb;101:255-63
pubmed: 26453962
Biomed Pharmacother. 2017 Nov;95:885-893
pubmed: 28903184
J Neurotrauma. 2010 Mar;27(3):555-63
pubmed: 20001584
Acta Neurochir (Wien). 2006 Mar;148(3):255-68; discussion 268
pubmed: 16311842
J Neurosci. 2005 Feb 16;25(7):1816-25
pubmed: 15716418
J Pharmacol Exp Ther. 2002 Sep;302(3):881-8
pubmed: 12183643
PLoS One. 2012;7(9):e45763
pubmed: 23029230
Nat Med. 2003 Sep;9(9):1173-9
pubmed: 12925848
Neuroreport. 2009 Aug 26;20(13):1161-6
pubmed: 19617854
Diabetes Obes Metab. 2017 Oct;19(10):1446-1453
pubmed: 28741871
ACS Pharmacol Transl Sci. 2019 Apr 12;2(2):66-91
pubmed: 31396586
Curr Pain Headache Rep. 2016 Jun;20(6):42
pubmed: 27184060
Brain Res. 2007 Jan 26;1130(1):197-205
pubmed: 17174280
Exp Neurol. 2007 Feb;203(2):293-301
pubmed: 17125767
Cell Metab. 2017 Aug 1;26(2):343-352.e2
pubmed: 28768173
J Neurosci Res. 2011 Jul;89(7):1103-13
pubmed: 21472764
Front Neurosci. 2017 Sep 06;11:500
pubmed: 28932183
Dan Med J. 2012 Oct;59(10):A4519
pubmed: 23158895
J Neuroinflammation. 2015 Mar 07;12:45
pubmed: 25879458
Cell Transplant. 2017 Sep;26(9):1560-1571
pubmed: 29113464
Behav Brain Res. 2001 Nov 1;125(1-2):141-9
pubmed: 11682105
Lancet. 2017 Oct 7;390(10103):1664-1675
pubmed: 28781108
Nat Med. 2018 Jul;24(7):931-938
pubmed: 29892066
J Neurosci Methods. 2016 Oct 15;272:4-18
pubmed: 26868732
Eur J Pharmacol. 2011 Jan 10;650(1):249-55
pubmed: 20951130
Gastroenterology. 2007 May;132(6):2131-57
pubmed: 17498508
Behav Brain Res. 1999 Mar;99(2):191-200
pubmed: 10512585
Neurobiol Dis. 2013 Jun;54:1-11
pubmed: 23454194
Neurobiol Dis. 2019 Apr;124:439-453
pubmed: 30471415
Front Cell Neurosci. 2012 Dec 12;6:58
pubmed: 23248582
Nat Rev Endocrinol. 2009 May;5(5):262-9
pubmed: 19444259
J Neurochem. 2010 Jun;113(6):1621-31
pubmed: 20374430
Alzheimers Dement. 2016 Jan;12(1):34-48
pubmed: 26327236
J Neurochem. 2015 Dec;135(6):1203-1217
pubmed: 25982185
J Biol Chem. 2002 Sep 27;277(39):35920-31
pubmed: 12114522
J Neurotrauma. 2012 Sep;29(13):2283-96
pubmed: 22642287
Br J Anaesth. 2007 Jul;99(1):4-9
pubmed: 17573392
Brain Res. 2000 Aug 25;874(2):123-30
pubmed: 10960596
J Biol Chem. 2003 Jan 3;278(1):471-8
pubmed: 12409292
J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):857-62
pubmed: 12810767
J Diabetes Investig. 2010 Apr 22;1(1-2):8-23
pubmed: 24843404
J Neurotrauma. 2009 Aug;26(8):1307-14
pubmed: 19317611
Neurobiol Aging. 2010 Sep;31(9):1495-502
pubmed: 18930564
Neuroreport. 2016 Jan 6;27(1):23-32
pubmed: 26555034
Diabetes. 2009 Feb;58(2):318-28
pubmed: 18984744
Neuropharmacology. 2018 Jul 1;136(Pt B):260-270
pubmed: 28927992
Eur J Pharmacol. 2017 Oct 5;812:82-90
pubmed: 28666800
Phys Med Rehabil Clin N Am. 2011 Nov;22(4):683-700, ix
pubmed: 22050943